



A review on Infantile hemangiomas.

Ananthu R ¹, Shobin B Varghese ², Abhirama B R ³, Julia J J ⁴, Prasobh G R ⁵

¹ Student, Sree Krishna College of Pharmacy and Research centre, Parassala, Thiruvananthapuram.

² Student, Sree Krishna College of Pharmacy and Research centre, Parassala, Thiruvananthapuram

³ Professor, Department of pharmacy practice, Sree Krishna College of Pharmacy and Research centre, Parassala, Thiruvananthapuram.

⁴ Assistant professor, Department of pharmacy practice, Sree Krishna College of Pharmacy and Research centre, Parassala, Thiruvananthapuram.

⁵ Principal, Sree Krishna College of Pharmacy and Research centre, Parassala, Thiruvananthapuram.

Abstract:

Propranolol is the first generation drug of β -blocker family, which is added in the medical utility for tachycardia and high blood pressure in the 1960s. However, the occasional discovery of propranolol within side the involution of infantile hemangiomas (IHs) delivered us a brand new perspective. IHs are the most common infantile tumor, affecting 4–10% newborns. So far, oral propranolol is the first-line remedy for IHs treatment. At the equal time, local injection and topical propranolol are developing. Despite the global utility, the specific mechanism of propranolol of IHs has now no longer been absolutely studied. In this article, we reviewed and summarized the modern facts on pharmacology, mechanism, efficacy, and destructive outcomes of propranolol. Novel layout of biomaterials and bioactive molecules are wished for new remedy and best pathway to gain the minimum powerful treatment concentration and put off the destructive outcomes.

Introduction

Propranolol became a choice of treatment initially in 1960s.¹ After the serendipitous locating that propranolol expanded the recuperation of IHs via way of means of the French team,^{2,3} three more researches proved the efficacy and propranolol is now identified because the first-line medicine for IHs.⁴ In the beginning, oral propranolol begins off evolved from 1 mg/kg/day to 2–3 mg/kg/day for as a minimum 6–12 months.⁴ For similarly examination, 1.5–2.0 mg/kg/day is taken into consideration because the top-quality dosage.⁵ IHs arise in approximately 4–10% infants, inflicting them the most common infantile neoplasms.⁶⁻

⁹ The pathology of IHs is the hyperplasia of the endothelial cells. Distinguished from different vascular

anomalies, IHs are expressing glucose transporter-1 protein (GLUT-1).^{6,7,10,11} There are stages with inside the development of IHs, proliferative segment and involution segment. Due to the involution, maximum of the IHs want no intervention and simplest 10% of the patients require medicine.¹² Though propranolol is the right choice for IHs, the adverse events, as an example bradycardia and hypoglycemia are noticeable. Other than the medicine, surgical operation and laser control are of fantastic importance. However, along with the emergence of the propranolol therapy, the ones interventions are not often used.¹¹ Generally speaking, surgical operation ought to now no longer be advocated during the toddler period due to the excessive anesthetic risks.¹³⁻¹⁵ In the subsequent situations, surgical operation intervention will betaken into consideration. The first is that the neighborhood remedy and medicine aren't working. The 2nd is that the advanced surgery that could be useful for the similar reconstruction, regarding the ears or the eyelids. The third is that the lesions are constrained in without problems resectable areas. The ultimate is that the surgical operation ought to be executed and there are of no variations with inside the surgery timing.¹³⁻¹⁵ Pulsed-dye laser (PDL) has been carried out for IHs in many years. It is extensively well-known that PDL is secure and powerful in IHs. The associate daspect results consist of skin atrophy, bleeding, scar, and pigment variations.¹⁶ Since the arrival of propranolol treatment, the exercise is less not unusual place. Some researchers pronounced that PDL possessed a better prevalence of aspect activities with inside the little one period.^{15,17} PDL can most effective put off the superficial lesions and the deep tissues aren't affects, which ends up in the residual changes.^{18,19} The mixture of Nd:YAG laser and PDL ought to clear up the difficulty referred to before.²⁰ Nd:YAG laser is capable of penetrate 5–6 mm deep with inside the tissue. Hence, the mixture is powerful and convey a brand new angle with inside the laser therapy. In this review, we awareness at the position of propranolol in IHs. Over the many years of scientific exercise, the precise mechanism of propranolol motion has now no longer been completely investigated. Our goal to study and replace the curhire data on pharmacology, mechanism, efficacy, and negative impact of propranolol.

Pharmacology of Propranolol

Propranolol is a non-selective β -adrenergic receptor blocker. Its chemical method is 1-Isopropylaminothree-1-naphthyloxy-2-propanol ($C_{16}H_{21}NO_2$).²¹ It is processed into the hydrochloride salt for application. As a cardiovascular β -adrenergic receptor blocker, propranolol is usually recommended for hypertension, tachycardia, angina pectoris, and so on. It is likewise used to inhibit cardiac remodeling. In the hyperthyroidism, anxiety, and tremor, propranolol performs an essential position in controlling the sympathetic over reaction. There are a few different indications just like the prophylaxis of migraine, too.²² Propranolol's chemical shape is much like catecholamine, that will compete with the β -adrenergic receptors. Catecholamine works through the forming of a hydrogen bond among the hydroxyl ion and the receptors.¹ However, propranolol is loss of hydroxyl ion, not able to set off the receptors and keep the relative β -adrenergic activity. Propranolol additionally possess a membrane stabilizing activity by means of blocking the sodium and calcium channels.¹ But the phenomenon most effective happens with inside the extraordinarily excessive dose, and has no scientific meanings. The healing impact of propranolol for IHs is thru the law of renin-angiotensin system (RAS).²³⁻²⁸ IHs' endothelium indicates an expression of additives of RAS²⁵ and pro-renin receptor.²⁶ Researchers has found that angiotensin II(ATII) promotes the capillary

proliferation of IHs and in vitro generates a blast-like biological shape probably to the liner endothelial cells in IHs.²⁵ The different opinion approximately the propranolol mechanism is angiogenesis suppression. Up regulation of angiogenesis transcription elements like hypoxia-inducible factor (HIF-1 α) and vascular endothelial increase factor-A (VEGF-A) is not unusual place in neonates with IHs,²⁹ and when used with propranolol we will look at a high-quality dose-dependent discount in HIF-1 α and the VEGF-A.³⁰⁻³² Overall, propranolol performs an effective position on IHs.

Pharmacokinetically, all the oral propranolol is almost absorbed from the intestine. But the blood concentrations are variable. After oral intake, propranolol can be detected inside 30 min and reaches height at approximately 60 min. The common form is propranolol hydrochloride which launch slowly and height plasma concentrations are attained after approximately 6h. The liquid shape of propranolol ought to be taken proper after meals. And the pharmacokinetic evaluation indicates that the best blood awareness is located at three hours after administration.³³ There is first by skip removal impact of liver, so after oral administration the powerful flow propranolol to the lesion vicinity is depending.³⁴ Propranolol is significantly disbursed in many organs and might by skip thru the blood mind barrier. Over 90% of the plasma propranolol is certain to the blood protein. Propranolol follows the primary order removal rule, impartial of blood awareness and intake dosage. Propranolol is excreted from the kidney, so the half-lifestyles correlates the renal function

Biological Effects of Propranolol

Propranolol has been implemented with inside the remedy of IHs for extra than ten years. It is broadly mentioned that the have an effect on of propranolol on IHs is predicate dat the RAS modulation.²⁸ 6 months remedy is taken into consideration as a better duration.³⁵ In lots of articles, the organic efficacy of propranolol to IHs is verified. As a essential transcription component in angiogenesis, HIF1 α takes a essential element in IHs. More and extra IHs infants are stated tormented by perinatal hypoxia. We could deduce that the growth of HIF-1 α effects from the hypoxic events, like prematurity and pre-eclampsia.^{36,37} ATII is worried with inside the method of HIF-1 α up regulation. Thus, the inhibiting capacity of propranolol to ATII may exert massive consequences on prohibiting angiogenesis thus down regulating the pro-angiogenesis pathway with the aid of using HIF-1 α .³⁷

Propranolol may additionally feature through improving capillary endothelium apoptosis.^{38,39} Through the β -adrenergic Blockade, propranolol decreases the tumor blood with the drift way of means of improving vasoconstriction and inhibiting vasodilation.³⁸

Oral propranolol is made of specific isomers, S-propranolol and R-propranolol.^{23,40} S-propranolol possess the lively β -adrenergic blocking off capacity, whilst R-propranolol is an inactive isomer. Some students believe it's far the R-propranolol participates with inside the healing course of IHs.^{23,40} Compared with the manipulate groups, angiopoietin is appreciably decrease expressed with inside the R-propranolol remedy each in vitro and with inside the murine models. Therefore, R-propranolol interfere the IHs through down regulating angiogenesis elements after which inhibit angiogenesis.²³ R-propranolol gets rid of the hemangiomas and activates a few tumor suppression genes as betaine homocysteine methyl transferase and

early increase response-1 genes.²³ The above brings us a new technique of innovating the scientific remedy to apply the R-propranolol on my own to realize tumor decrement while avoiding side effects.

As all of us know, there are enantiomers of propranolol, R-propranolol and S-propranolol. Propranolol is particularly utilized in cardiovascular and neural system. Nevertheless, the efficacy of propranolol isn't always proportional to the receptors level.^{41,42} In the similarly studies, researchers unveil the function of R-propranolol and S-propranolol. The researchers proposed that R-propranolol confirmed power at the SOX18 transcriptional aspect after which performed an critical function with inside the anti-angiogenic process.⁴⁰ SOX18 is extensively studied and characteristic with inside the neo-vascularization.^{43,44} This concept also helps our thoughts the it's far the R-propranolol that functions because the essential mediator in IHs.

Even though the huge randomized managed trial (RCT) is the gold wide spread for the effectiveness comparison among propranolol and steroids, it isn't always practicable or ethical. We use different strategies to compare. In a retrospective cohort evaluation,⁴⁵ the researchers in comparison sixty eight neonates dealt with propranolol at 2 mg/kg/day, with forty two babies deal with oral steroids at 4mg/kg/day. The evaluation of the outcomes is rectified with matching ages, lesion area and lesion type. The neonates deal with propranolol indicates more lesion clearance that the ones present process steroids therapy. In the instances babies want secondary surgery, propranolol is likewise a higher choice in comparison to steroids (12% vs 29%, $P < 0.01$).⁴⁵

Use of Propranolol in IHs

After the serendipitous finding, the vintage drug, propranolol has its new software for IHs.³ Nowadays, oral propranolol is confirmed to be the primary-line medicine in IHs. The exploration of nearby management pathway as nearby injection and topical software is in development.⁴⁹ IHs are the maximum typical infant tissue benign neoplasms. IHs are the bizarre vascular hyperplasia and can exist almost anywhere over the frame. IHs are generally identified from one week to at least one month, might also additionally present a fast development in a single or 3 months. Approximately, 90% of IHs slowly involute into fibrous and adipose tissue. Most of the tumors are capable of remedy and want no intervention, while the complicated ones must be deal with. Those encompass IHs that would cause huge scar, disfiguration and dysfunction, airway or hepatic IHs, ulceration, and associated latent abnormalities.^{50,51}

Diagnosis of maximum IHs is finished even though the scientific facts and bodily examinations. The preliminary scientific history must comprise the delivery history, the timing of IHs discovery, the period of IHs growing, the timing of cessation of IHs development, and the complications.^{11,16,52-56} After the primary diagnosis, the sufferers must come for a follow-up go to evaluate the sicknesses at 1–3 months. The medical doctors should compare the overall repute and the certain facts about the IHs such as site, size, color, quantity and the indications of involution.^{57,58} At the equal time, imaging substances should be accumulated sequentially from every next go to the 6 months after intervention.^{8,59} The remedy consequences must be envisioned via way of means of visible analog scale (VAS) and are divided into 4 levels, excellent, good, terrible and no response.⁶⁰

IHs must be outstanding from different vascular tumors, regarding benign neoplasms like congenital hemangiomas (CHs), borderline neoplasms like Kaposiform hemangio endothelioma, and malignant neoplasms like epithelioid hemangio endothelioma. IHs should be diagnosed from vascular malformations, too^{7,61-63}. CHs are completely mature at delivery. They do now no longer have specific stages like IHs.^{6,61-63} CHs display a sample like bluish-purple mass with dilated capillaries at the floor or gray neoplasms Vascular malformations are born bizarre vascular tissues. They are strong after exertions and do now no longer have correct proliferating or involution phase. They simply develop with frame increase. The pathogenic stimuli such as infection, hormone variation, harmand so forth can make bigger the malformations.^{7,10,54}

The management dose is usually recommended beginning from 1mg/kg/day to cardiovascular right 2–3mg/kg/day in many posted scientific guidelines^{8,11,57,64}. Based on existent articles, the goal dosage is the use of the empirical maximal dosage of 2–3 mg/kg/day to deal with IHs.⁶⁵ To date, there is lacking of large-scale RCTs to confirm the date, there may bemissing of big-scale RCTs to verify the minimum dosage to acquire the speedy involution of IHs. The American guidelines¹¹ advise remedy at 2–3mg/ kg/day. The Spanish consensus guidelines⁶⁶ advise remedy at 3mg/kg/day, but the Australian guide traces deliver a maximal dosage of 1–2mg/kg/day, unless a decrease dosage is clinically effective.⁵⁷

The perfect timing of beginning intervention isn't reported in maximum acknowledged pointers, and there aren't any associated trials emphasise the top of the line beginning time factor and period of remedy. Conventionally, remedy need to be started as quickly as feasible, with inside the early segment of IHs development, earlier than the irreversible harm is initiated.⁵⁷ The period of propranolol utilization is suggested for at the least six months, generally lasting twelve months or longer.⁶⁶⁻⁶⁸ Some researchers advise the remedy is sustained until the involution of IHs, and a mean of 14 months is suggested.⁶⁹

After reviewing all of the materials, we advise the goal propranolol dosage is 2-3 mg/kg/day and the remedy have to begin from 0.7–1.0 to 2.0–2.5 mg/kg/day in 3 divided doses at an language of at the least three days. Propranolol has a maximal have an effect on coronary heart muscles and blood strain in 3 hours after application⁷⁰ and the drug response regularly occurs with inside the preliminary remedy.⁷¹ Therefore, maximum professionals advise the blood strain and coronary heart rate need to be monitored with inside the first and second hour after the preliminary management and every increment. If there may be no apparent variant for those periods, sufferers are imagined to be strong in the course of the propranolol intervention.^{8,70} However, the Australian pointers suggest the ones toddlers with out chance elements ought to begin the medication at domestic and the tracking technique is simplest for the ones on the chance of hypoglycemia and associated medical issues.⁵⁷ In the entire remedy procedure, everyday subsequent tracking is of necessity.^{8,57} The ulceration in IHs is seemed as a chance factor. Ulceration can reason bleeding, pain, contamination and secondary lesions.^{72,73} The ulcerated kind desires intervention as quickly as feasible and the oral propranolol remains the primary desire on the dose of 2–3mg/kg/day. In the path of ulcerated IHs, bleeding have to be taken into consideration. Though bleeding is the major concern, the bleeding diploma of ulcerated IHs is minor and may be without problems treated with compression.^{72,73}

Though oral propranolol is properly enduring, the medication remains dealing with numerous detrimental events,⁶⁹ which leads to extra research approximately neighborhood intervention like topical propranolol.⁷⁴ But in maximum researches, oral propranolol is the first-rate option.⁷⁴ In a medical trial, which is ready the assessment among oral propranolol at 3mg/kg/d and 1% topical propranolol three instances a day, the consequences show a quicker healing impact with inside the oral propranolol group. In conclusion, topical propranolol remedy is much less effective and have to be taken into consideration simplest while the sufferers suffer from excessive aspect effects.

In a big meta-evaluation of research, propranolol responding rate reaches 82–100%.⁷⁵ Hermans et al⁷⁶ find the remedy impact begins off evolved inside three days, and after 2.0–2.5mg/kg/day for 12–18 months' oral propranolol treatment there may be apparent development in 99% of sufferers. In placebo managed RCTs,^{35,77} expected treating outcomes are determined in 5 weeks remedy, with persistent amelioration in lesions over the technique, evaluation to the managed placebo groups. In a potential cohort study, 50% of all 188 neonates dealt with 2 mg/kg/day oral propranolol for a mean period of eight months receives a perfect response, over 70% lesion deduction. Only 20% toddlers acquired a much less pleasant outcome, much less than 30% discount with inside the lesion length. In this research, a crucial courting among early remedy and improved treatment efficacy, with 45% having horrific responses while the intervention commenced in 18–27 months of age, and simply 7% having horrific reaction while the remedy is among 0–2 months of age.⁷⁸

The phenomenon of rebound increase is located in up to 25% with inside the IHs sufferers with propranolol remedy.^{75,78-80} In a cohort observe, girl neonates, superior interruption of medication (previous to nine months of age) and deep IHs are taken into consideration as feasible pathogenic elements. The researchers find out a profound discrepancy of rebound increase chance of the babies in which the termination of remedy is earlier than 9 months of age in comparison to after 24 months of age. In similarly evaluation of this research, ladies and deep IHs are growing the rebounding chance to the opposite elements just like the length and area of lesions.⁷⁹

Most of the researches rely upon the scientific doctors to degree the morphology of the lesions and subjectively examine the diploma of amelioration. Moreover, a few studies describe the variations with wide categories, excellent, moderate, or badreaction. These boundaries are loss of unique requirements to differentiate, simplest through the percent of lesion discount after intervention. Due to the deficiency of the standardized measurement, the results of the research are nonetheless subjective and now no longer convincing. The above emphasizes the significance to use a standardized rule to assess the scientific manifestation of IHs.⁸¹

Adverse Effects

Propranolol has been taken into secure with fewer unfavourable out consideration comes in comparison to the overall management of steroids.^{45,82} In a retrospective cohort observe approximately the evaluation among propranolol and steroids in IHs babies, the steroids organization gift a 100% adverse issues, in comparison to 1% with inside the propranolol organization. The unfavourable occasion with inside the propranolol organization is hypoglycemia, a rather uncommon hardship with few reports. Other not

unusual place complications encompass sound asleep issues,⁸³ agitation and gastrointestinal issues aren't said on this article.⁸⁴ To date, there's no large-scale RCT reading at the unfavourable outcomes of propranolol treatments. There are numerous headaches quotes suggested from 7% to 96%,^{56,58,76} however, simplest approximately 3% of IHs neonates be afflicted by excessive unfavourable headaches and in need of propranolol termination.⁵⁸ Phillips et al located the damaging impact charge of oral propranolol on IHs babies is 27%. And the maximum regular worry is sleep ailment (14%). Four percentage of the take a look at youngsters necessitate propranolol cessation.⁷⁸ There are many feasible motives leading to the damaging outcomes charge. Nevertheless, sleep ailment, hypotension, bradycardia and hypoglycemia are of consistence in diverse articles.⁸⁵ Only some different complications are diversely reported. Patient demographics and individuals variations are feasible pathogenic factors.

In a multicenter placebo managed RCT,³⁵ they design 3 analyzing groups, propranolol 1mg/kg/day, propranolol 3mg/kg/day and a placebo institution in a 6 months route of remedy. The charge of damaging outcomes is 90%, 96% and 76% respectively. The reason why the placebo institution reveals a tremendously excessive aren't discussed. The not unusual place damaging activities are agitation, sleep disturbance, gastrointestinal disturbance inclusive of vomiting, diarrhea, constipation, cool peripheries, and bronchitis that are much like different articles. The different critical results like bradycardia, hypotension, and hypoglycemia are rare. While in any other take a look at, the researchers use a low propranolol dose of 1.5–2.0 mg/kg/ day.⁸⁶ They discover a as an alternative correct final results with 7% of damaging occasion charge and there may be no want to prevent the medicine.

To sum up, the not unusual place damaging activities of oral propranolol for IHs are napping ailment and agitation, which can also additionally result in the interruption of remedy.^{87,88} Other known damaging activities contain bradycardia, hypotension, bronchial disturbance and hypoglycemia. Mild facet outcomes are digestive ailment (emesis, diarrhea or astriction) and anorexia.⁸⁹

Although short-time period facet outcomes of oral propranolol are extensively studied, there may be no systemic take a look at the underlying effect at the cognitive feature. The propranolol is lipophilic and is without problems connected to the mind blood barrier (BBB), which allow propranolol to motive primary apprehensive system (CNS) influence.⁹⁰ To date, there may be a loss of published articles to research the long-time period CNS outcomes inclusive of cognitive level, memory, sleep, feelings and so on. According to a small case manipulate take a look at of eighty two youngsters with IHs, they get no profound distinction of motor feature, communication, social potential and bodily improvement among the propranolol institution and the non-propranolol institution on the age of four.⁹¹ But the above-cited take a look at is restricted via way of means of its small scale and the simplest effects on the age of four. On the contrary, researches at the CNS feature of person treated with propranolol discover the difference on memory, emotion, sleep and intellectual reputation among propranolol institution and the placebo institution.⁹² The discrepancy of propranolol damaging outcomes among youngsters and adults can also additionally characteristic to neural plasticity of the babies.

Propranolol is the primary-line medicine for IHs with apparent damaging activities. It is of extraordinary significance to broaden a singular biomaterial, bioactive molecules or different perfect pathway to reap the minimum powerful remedy concentration, navigate unique drug shipping and eliminate the damaging outcomes. The golden-wellknown of remedy guiding principle has now no longer reached a consensus. This reputation is as a result of the absence of huge RCTs and there are simplest some small research, maximum of that are cohort research and meta-evaluation and not using a unified standards to degree scientific issues. At present, scientific docs and researchers have to rely upon the cutting-edge knowledge, enjoy and published substances to manual remedy and studies and do greater clinical researches to offer higher remedy for the IHs patients.

Methods

Patients

This have a look at enrolled 578 sufferers present process remedy for IH on the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, People's Republic of China, from January 2010 to December 2012. The human challenge protocol became authorized through the Ethics Committee of the Ninth People's Hospital (IRB:201548). Patients had been identified with proliferating IH through the Department of Oral-Maxillary Head and Neck at the Ninth People's Hospital Shanghai and written informed has the same opinion had been acquired from the dad and mom or guardians including snap shots to be posted for this have a look at according with The World Medical Association Declaration of Helsinki. A standardized database recorded affected person details, which included affected person gender, age at remedy initiation, area and size of the lesion, medicine and dose, medical reaction, and headaches as a consequence of remedy and follow-up.

Propranolol Treatment

Prior to propranolol remedy, a colour sonography done to locate any viable congenital cardiac disturbances inclusive of atrioventricular block or bradycardia etc. For propranolol remedy, sufferers had been handled on an outpatient basis, and the imply time of remedy became 6 months. To limit headaches, oral propranolol became administered as soon as day by day at a dose of 1.0 mg/kg for sufferers more youthful than 2 months, even as it became administered two times day by day for sufferers older than 2 months. In the remaining month of remedy, the propranolol dose became halved for the primary 2 weeks. If no rebound occurred, the dose became in addition halved for the following 2 weeks earlier than propranolol remedy became discontinued completely. Patient frame weight became measured each 2 weeks and propranolol dosage became adjusted in accordance to the extrade of frame weight.

Advanced remedies

For sufferers with small tumor discount after remedy with propranolol for two weeks, oral prednisone became administered at a dose of 5mg each 2 days. For sufferers with complex hemangiomas and those nonresponsive to propranolol or prednisone remedy, pingyangmycin, IFN- α , or vincristine remedies had been implemented. These drug treatments had been used simplest with inside the second line or third line due to the side effects. For pingyangmycin remedy, sufferers had been intralesionally injected a day by day dose of

1mg for 2.5 months. For IFN- α remedy, sufferers had been subcutaneously injected a day by day dose of 3×10^6 Unit/m² for three months. For vincristine remedy, sufferers had been intravenously administered a dose of 1.0 mg/m² each 2 weeks with an c program language period of 1 week among rounds and a complete of two rounds. For sufferers with chromatosis or telangiectasia after propranolol remedy, a 0.5% answer of timolol maleate became implemented topically over the lesion floor the use of a cotton swab three instances day by day. If no reaction became found after 2 weeks of remedy with timolol maleate, high-frequency pulsed dye laser became implemented the use of a wavelength of 595 nm and a pulse period of 10 ms.

Therapy evaluation

Photographs had been taken and ultrasound examinations had been executed to assess remedy efficacy. Ultrasound examination can degree the width and the peak of IH lesions. Volume = width \times height² /2.⁹³ Both pix and ultrasound examinations had been finished previous to remedy, at 2 weeks, 1 month, and three months following remedy as well as at every follow-up visit. Photographs can permit direct visualization of quantity extrade, and ultrasound examinations can offer the quantitative data. Responses to propranolol had been graded as follows: a tumor discount extra than 75% became taken into consideration an “excellent” reaction; a discount extra than 50% a “suitable” reaction; a discount of 25% or much less a “bad” reaction; and a 0% discount became taken into consideration “nonresponsive.”

Statistical evaluation

Response rate (RR) to propranolol became summarized according to affected person demographic or sickness traits using evaluation of paired t-test, with P,0.05 taken into consideration enormous. Software SPSS (Version 19.0; IBM Corporation, Armonk, NY, USA) became used to carry out the statistical evaluation.

Results

Patient demographic and sickness traits

This examine became carried out in a cohort of 578 sufferers with imply age of 6.12 ± 5.29 months (range, 1–12 months). The average male-to-lady ratio became 1:4.7. 97 (16.8%) of 578 sufferers had been premature, and progesterone became the maximum not unusual placetocolytic agent used for the remedy of moms all through the gestational period. The maximum not unusual place anatomic websites on this examine had been lips (17.5%) and the eyelids (15.4%). The imply length of hemangioma became 20.26 ± 19.57 cm². 529 (91.5%) hemangiomas had been superficial hemangiomas, 38 (6.6%) had been subcutaneous hemangiomas, and 11 (1.7%) had been mixed hemangiomas.

Patient reaction to propranolol remedy

Our consequences discover enormous variations in RR for different a while of sufferers, with the youngest sufferers having the maximum RR (P,0.05, t-test). RR to propranolol with inside the group more youthful than 2 months became 98.1%, compared with 93.3% in sufferers older than 2 months and more youthful than eight months and 73.7% in sufferers older than eight months. The distinction became now no longer associated with gender. In addition, as for the tumor location, RR became maximum while tumors had been positioned with inside the parotid region and lowest with inside the lip region (RR: 97.8%, 85.1%,

P,0.05, t-test). However, RR to propranolol became now no longer enormous for unique forms of IH (superficial, subcutaneous, or mixed hemangiomas RR: 94.5%, 91.7% vs 87.3%, P,0.05, t-test). Moreover, RR to propranolol became in addition characterised as follows: 186 (32.2%) of 578 sufferers exhibited excellent reaction; 317 (54.8%) exhibited suitable reaction; 57 (9.9%) exhibited bad reaction; and 18 (3.1%) had been nonresponsive. The imply time of remedy became 6 months (range, 3–12 months).

Patient reaction to superior remedies

For sufferers with bad reaction or folks who had been non attentive to propranolol (75 sufferers), oral prednisone became delivered to the remedy regimen. After remedy with prednisone, lesions in 67 (89.3%) of 75 sufferers involuted without rebound. As for the ultimate nonresponsive sufferers, superior remedies had been administered inclusive of pingyangmycin (2 sufferers), IFN- α (1 affected person), vincristine (2 sufferers), or surgical intervention (3 sufferers). No rebound became discovered in those cases, and sufferers all confirmed high-quality consequences to superior remedies.

After propranolol remedy, 131 sufferers exhibited incompletely involuted hemangiomas (chromatosis or telangiectasia) and had been in addition handled with timolol maleate (89 sufferers) or pulsed dye laser (42 sufferers). 117 (89.3%) of 131 sufferers confirmed high quality reaction.

Overall, no sufferers in our examine evolved life threatening headaches; 23 (3.98%) of 578 sufferers evolved minor headaches inclusive of sleep disturbance (10 sufferers), diarrhea (7 sufferers), and bronchospasm (5 sufferers). The imply length of follow-up became 3.08 ± 0.8 3 years. For sufferers with excellent (186 sufferers) or suitable propranolol reaction (317 sufferers), rebounds of IHs had been simplest detected in 6 (1.2%) of 503 sufferers, which diminished away with additional propranolol remedy for no extra than three months.

Discussion

Currently, there may be no manner to expect the final results of proliferative IH.⁹⁴ A subset of IH can doubtlessly be associated with mental trauma of babies and tension of parents, which calls for early intervention, hence calling for the anatomic web page of hemangiomas on this examine. the reevaluation of traditional “watch and wait” approaches For IH remedy.⁹⁵ So far, special modalities have been mentioned for the remedy of IHs, inclusive of surgical operation (laser surgical operation and cryosurgery) and pharmacotherapy (β -blocker, corticosteroids, INF- α , and vincristine). As a β -blocker, propranolol has been established to be very powerful and safe for IH remedy, which dramatically modifications IH therapeutic approach and makes propranolol update corticosteroids as the first-line remedy for IH.⁹⁶

Although no general routine for IHs has been established, remedy of IH need to be taken cautiously and instituted with rigorous guidelines. In preceding studies, we handled IH sufferers with oral propranolol as inpatients for 48 hours and closely monitored their blood stress and coronary heart rates. No obvious modifications had been determined. In this study, IH sufferers had been handled with oral propranolol in an outpatient setting. The dose became now no longer particular due to the fact the capacity face outcomes had been now no longer clear. So we initiated propranolol remedy at a dose of 1–2 mg/kg/d, and then tapered

propranolol over a 1-month duration to minimize the threat of withdrawal reaction. In addition, oral propranolol became administered after meals to lessen the threat of hypoglycemia. The exquisite efficacy of propranolol for the remedy of IH became determined now no longer most effective with inside the speedy increase section however additionally with inside the following involution section.⁹⁷ Therefore, the period of propranolol remedy for IH sufferers is likewise very important for medical outcome. In this study, the period of propranolol remedy lasted a median of 6 months, and remedy became terminated whilst the toddlers reached 1 - 12 months of age.⁹⁸

The efficacy of propranolol on our IH affected person cohort became encouraging, with accurate RR, few rebounds, and limited face outcomes. All IH sufferers receiving superior remedy exhibited final outcome.⁹⁹ For sufferers with excellent or accurate reaction to propranolol, 131 (26%) exhibited telangiectasia and chromatosis after remedy and had been further handled with a 0.5% answer of timolol maleate or pulsed dye laser for entire involution.¹⁰⁰ Timolol is a β -blocker and typically used to deal with nasal telangiectasia and epistaxis.¹⁰¹ Timolol additionally performs a vital position with inside the remedy of superficial IH.¹⁰² Compared with systemic oral propranolol remedy for IH treatment topical timolol remedy is non systemic and related with much less aspect effects.¹⁰³⁻¹⁰⁴

Despite the achievement of propranolol in IH remedy, the underlying mechanism of propranolol remedy stays elusive. A preceding have a look at verified that propranolol targets hemangioma stem cells through CAMP and mitogen-activated protein kinase regulation.¹⁰⁵ In this have a look at, we determined that RR to propranolol turned into drastically better in more youthful sufferers, with sufferers more youthful than 2 months having the best RR, which is in step with preceding findings. We suppose estrogen is the critical factor. In our simple research, on the equal time, we determined that estrogen promoted angiogenesis through blended with ER α to upregulating the expression of VEGF-A in hemangioma derived stem cell, selling proliferation of IHS. Propranolol inhibits angiogenesis through down regulating the expression of VEGF in hemangioma-derived stem cells.¹⁰⁶ In this have a look at while the affected person turned into more youthful, the hobby turned into stronger. So, a higher end result turned into completed while the sufferers had been more youthful than 2 months. However, in addition research are required to higher make clear the mechanism of propranolol in IH remedy.

Conclusion

After the serendipitous utility of propranolol on IHS babies, the docs have modified their concept on IHS treatment. To date, propranolol is the primary-line agent and provides awesome outcomes to the IHS patients. Based on articles' overview and our scientific enjoy, the recommendatory utilization of propranolol to IHS have to begin from 0.7–1.0 to 2.0–2.0mg/kg/d in 3 divided doses at an c programming language of as a minimum 3 days. And the primary medicine have to be done in medical institution to display the babies' general reputation after intervention. Oral propranolol is taken into consideration as a secure and powerful remedy; however, the damaging outcomes can't be neglected and the extra evidences and researches are wished for higher scientific results.

References

1. Ogrodowczyk M, Dettlaff K, Jelinska A. Beta-blockers: current state of knowledge and perspectives. *Mini Rev Med Chem.* 2016;16 (1):40–54. doi:10.2174/1389557515666151016125948.
2. Itinteang T, Chudakova DA, Dunne JC, Davis PF, Tan ST. Expression of cathepsins B, D, and G in infantile hemangioma. *Front Surg.* 2015;2:26. doi:10.3389/fsurg.2015.00026
3. Leaute-Labreze C, de la Roque ED, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. *N Engl J Med.* 2008;358(24):2649–2651. doi:10.1056/NEJMc0708819
4. Lopez-Gutierrez JC. Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid. *Eur J Pediatr.* 2019;178(1):1–6. doi:10.1007/s00431-018-3290-z
5. Koh SP, Leadbitter P, Smithers F, Tan ST. β -blocker therapy for infantile hemangioma. *Expert Rev Clin Pharmacol.* 2020;13 (8):899–915. doi:10.1080/17512433.2020.1788938
6. Wildgruber M, Sadick M, Muller-Wille R, Wohlgenuth WA. Vascular tumors in infants and adolescents. *Insights Imaging.* 2019;10(1):30. doi:10.1186/s13244-019-0718-6
7. Adams DM, Brandao LR, Peterman CM, et al. Vascular anomaly cases for the pediatric hematologist oncologists-an interdisciplinary review. *Pediatr Blood Cancer.* 2018;65(1):e26716. doi:10.1002/pbc.26716
8. Hoeger PH, Harper JJ, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. *Eur J Pediatr.* 2015;174(7):855–865. doi:10.1007/s00431-015-2570-0
9. Yuan W, Wang X. Propranolol participates in the treatment of infantile hemangioma by inhibiting HUVECs proliferation, migration, invasion, and tube formation. *Biomed Res Int.* 2021;2021:6636891. doi:10.1155/2021/6636891
10. Steiner JE, Drolet BA. Classification of vascular anomalies: an update. *Semin Intervent Radiol.* 2017;34(3):225–232. doi:10.1055/s-0037-1604295
11. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guide-line for the management of infantile hemangiomas. *Pediatrics.* 2019;143(1):e20183475. doi:10.1542/peds.2018-3475
12. Jung HL. Update on infantile hemangioma. *Clin Exp Pediatr.* 2021. doi:10.3345/cep.2020.02061
13. Greene AK. Management of hemangiomas and other vascular tumors. *Clin Plast Surg.* 2011;38(1):45–63. doi:10.1016/j.cps.2010.08.001
14. Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. *Plast Reconstr Surg.* 2012;130(3):619–624. doi:10.1097/PRS.0b013e31825dc129
15. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. *Curr Probl Surg.* 2000;37(8):517–584. doi:10.1016/S0011-3840(00)80013-1
16. Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and management of infantile hemangioma. *Pediatrics.* 2015;136(4):e1060–e1104. doi:10.1542/peds.2015-2485
17. Witman PM, Wagner AM, Scherer K, Waner M, Frieden IJ. Complications following pulsed dye laser treatment of superficial hemangiomas. *Lasers Surg Med.* 2006;38(2):116–123. doi:10.1002/lsm.20294
18. Batta K, Goodyear HM, Moss C, Williams HC, Hiller L, Waters R. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. *Lancet.* 2002;360(9332):521–527. doi:10.1016/S0140-6736(02)09741-6
19. Kessels JP, Hamers ET, Ostertag JU. Superficial hemangioma: pulsed dye laser versus wait-and-see. *Dermatol Surg.* 2013;39(3 Pt 1):414–421. doi:10.1111/dsu.12081

20. Negosanti F, Silvestri M, Bennardo L, et al. Nd:YAG laser in association with pulsed dye laser for the treatment of PHACES syndrome. *Dermatol Reports*.2021;13(1):8751. doi:10.4081/dr.2021.8751
21. Town WG. The Merck index 13.2 CD-ROM edition from CambridgeSoft. *J ChemInfComput Sci*. 2004;44(5):1883–1885. doi:10.1021/ci0400462
22. Helena S. Martindale: the complete drug reference Brayfield Alison (Ed) Martindale: the complete drug reference pound 459 4,688pp pharmaceutical press 9780857111395 0857111396. *Emerg Nurse*.2014;22(5):12. doi:10.7748/en.22.5.12.s13
23. Sasaki M, North PE, Eley J, et al. Propranolol exhibits activity against hemangiomas independent of beta blockade. *NPJ PrecisOncol*.2019;3:27. doi:10.1038/s41698-019-0099-9
24. Itinteang T, Marsh R, Davis PF, Tan ST. Angiotensin II causes cellular proliferation in infantile haemangioma via angiotensin II receptor 2 activation. *J ClinPathol*.2015;68(5):346–350. doi:10.1136/jclinpath-2014-202794
25. Itinteang T, Brasch HD, Tan ST, Day DJ. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. *J PlastReconstrAesthet Surg*. 2011;64(6):759–765. doi:10.1016/j.bjps.2010.08.039
26. Van Schaijik B, Tan ST, Marsh RW, Itinteang T. Expression of (pro) renin receptor and its effect on endothelial cell proliferation in infantile hemangioma. *Pediatr Res*. 2019;86(2):202–207. doi:10.1038/s41390-019-0430-8
27. Sulzberger L, Baillie R, Itinteang T, et al. Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma. *J PlastReconstrAesthet Surg*. 2016;69(3):381–386. doi:10.1016/j.bjps.2015.10.020
28. Balakumar P, Jagadeesh G. Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders. *Hypertens Res*. 2011;34(11):1161–1170. doi:10.1038/hr.2011.113
29. Moisan F, Oucherif S, Kaulanjan-Checkmodine P, et al. Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade. *ProcNatlAcadSci U S A*. 2021;118:7. doi:10.1073/pnas.2018690118
30. Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, Gosain AK. Propranolol induces regression of hemangioma cells through HIF-1 α -mediated inhibition of VEGF-A. *Ann Surg*. 2012;256(1):146–156. doi:10.1097/SLA.0b013e318254ce7a
31. Tani S, Kunimoto K, Inaba Y, et al. Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. *Drug DiscovTher*. 2020;14(2):89–92. doi:10.5582/ddt.2020.03014
32. Pandey A, Singh A, Ali W, et al. Evaluation of effect of propranolol on serum vascular endothelial growth factor and tissue inhibitor of metalloproteinase-2 levels in infantile hemangioma. *J Indian AssocPediatr Surg*. 2020;25(2):96–102. doi:10.4103/jiaps.JIAPS_22_19
33. Takechi T, Kumokawa T, Kato R, Higuchi T, Kaneko T, Ieiri I. Population pharmacokinetics and pharmacodynamics of oral propranolol in pediatric patients with infantile hemangioma. *J ClinPharmacol*.2018;58(10):1361–1370. doi:10.1002/jcph.1149
34. Vignaduzzo SE, Maggio RM, Castellano PM, Kaufman TS. PLS and first derivative of ratio spectra methods for determination of hydrochlorothiazide and propranolol hydrochloride in tablets. *Anal Bioanal Chem*. 2006;386(7–8):2239–2244. doi:10.1007/s00216-006-0861-z
35. Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. *N Engl J Med*. 2015;372(8):735–746. doi:10.1056/NEJMoa1404710

36. Itinteang T, Tan ST, Guthrie S, et al. A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma. *J Clin Pathol*.2011;64(10):870–874. doi:10.1136/jclinpath-2011-200191
37. De Jong S, Itinteang T, Withers AH, Davis PF, Tan ST. Does hypoxia play a role in infantile hemangioma? *Arch Dermatol Res*. 2016;308 (4):219–227. doi:10.1007/s00403-016-1635-x
38. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. *Br J Dermatol*.2010;163(2):269–274. doi:10.1111/j.1365-2133.2010.09848.x
39. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. *In Vitro Cell Dev Biol Anim*. 2002;38(5):298–304. doi:10.1290/1071-2690(2002)038<0298:BBIAIC>2.0.CO;2
40. Overman J, Fontaine F, Wylie-Sears J, et al. R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. *Elife*.2019;8:e43026. doi:10.7554/eLife.43026
41. Wolter JK, Wolter NE, Blanch A, et al. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. *Oncotarget*.2014;5(1):161–172. doi:10.18632/oncotarget.1083
42. Chang PY, Huang WY, Lin CL, et al. Propranolol reduces cancer risk: a population-based cohort study. *Medicine*.2015;94(27):e1097. doi:10.1097/MD.0000000000001097
43. Villani R, Hodgson S, Legrand J, et al. Dominant-negative Sox18 function inhibits dermal papilla maturation and differentiation in all murine hair types. *Development*.2017;144(10):1887–1895. doi:10.1242/dev.143917
44. Francois M, Caprini A, Hosking B, et al. Sox18 induces development of the lymphatic vasculature in mice. *Nature*.2008;456 (7222):643–647. doi:10.1038/nature07391
45. Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. *Arch Dermatol*.2011;147(12):1371–1376. doi:10.1001/archdermatol.2011.203
46. Kardasevic M, Dinarevic SM. Infantile sacral region hemangioma and combination treatment with propranolol and topical timolol: case review and reference review. *Med Arch*. 2021;75(2):158–161. doi:10.5455/medarh.2021.75.158-161
47. Kridin K, Pam N, Bergman R, Khamaysi Z. Oral propranolol administration is effective for infantile hemangioma in late infancy: a retrospective cohort study. *Dermatol Ther*. 2020;33(3):e13331. doi:10.1111/dth.13331
48. Costa MC, Andrade OGC, Pereira LC, Costa IMC. Success in the use of oral propranolol in the treatment of infantile hemangioma in nasal tip - Report of two cases. *An Bras Dermatol*. 2020;95(2):207–209. doi:10.1016/j.abd.2019.05.005
49. Saerens J, Gutermuth J, Janmohamed SR. An infant with localized vasoconstriction following topical propranolol exposure for infantile hemangioma. *Pediatr Dermatol*. 2021;38(1):263–264. doi:10.1111/pde.14475
50. Kreshanti P, Putri NT, Martin VJ, Sukasah CL. The effectiveness of oral propranolol for infantile hemangioma on the head and neck region: a case series. *Int J Surg Case Rep*. 2021;84:106120. doi:10.1016/j.ijscr.2021.106120
51. Ishikawa K, Fujita M, Takeda T, et al. Ulcerated infantile hemangioma of the hard palate: diagnostic treatment with oral propranolol. *J Craniofac Surg*. 2020;31(6):e600–e602. doi:10.1097/SCS.0000000000006666
52. Chung SH, Park DH, Jung HL, et al. Successful and safe treatment of hemangioma with oral propranolol in a single institution. *Korean J Pediatr*.2012;55(5):164–170. doi:10.3345/kjp.2012.55.5.164

53. Blatt J, Morrell DS, Buck S, et al. β -blockers for infantile hemangio-mas: a single-institution experience. *ClinPediatr*. 2011;50 (8):757–763. doi:10.1177/0009922811405517
54. Giese RA, Turner M, Cleves M, Gardner JR, Richter GT. Propranolol for treatment of infantile hemangioma: efficacy and effect on pediatric growth and development. *Int J Pediatr*. 2021;2021:6669383. doi:10.1155/2021/6669383
55. Park M, Jung HL, Shim YJ, et al. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes. *Pediatr Res*. 2020;88(5):749–755. doi:10.1038/s41390-020-0862-1
56. Yun YJ, Gyon YH, Yang S, Lee YK, Park J, Park M. A prospective study to assess the efficacy and safety of oral propranolol as first-line treatment for infantile superficial hemangioma. *Korean J Pediatr*. 2015;58(12):484–490. doi:10.3345/kjp.2015.58.12.484
57. Smithson SL, Rademaker M, Adams S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. *Australas J Dermatol*. 2017;58(2):155–159. doi:10.1111/ajd.12600
58. Leaute-Labreze C, Boccara O, Degrugillier-Chopin C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. *Pediatrics*. 2016;138(4):e20160353. doi:10.1542/peds.2016-0353
59. Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. *Pediatrics*. 2012;130(2):e314– e320. doi:10.1542/peds.2011-3683
60. Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. *PediatrDermatol*. 2012;29(1):28–31. doi:10.1111/j.1525-1470.2011.01664.x
61. Kollipara R, Odhav A, Rentas KE, Rivard DC, Lowe LH, Dinneen L. Vascular anomalies in pediatric patients: updated classification, imaging, and therapy. *RadiolClin North Am*. 2013;51(4):659–672. doi:10.1016/j.rcl.2013.04.002
62. Johnson EF, Davis DM, Tollefson MM, Fritchie K, Gibson LE. Vascular tumors in infants: case report and review of clinical, histopathologic, and immunohistochemical characteristics of infantile hemangioma, pyogenic granuloma, noninvoluting congenital hemangioma, tufted angioma, and kaposiformhemangioendothelioma. *Am J Dermatopathol*. 2018;40 (4):231–239. doi:10.1097/DAD.0000000000000983
63. George A, Mani V, Noufal A. Update on the classification of hemangioma. *J Oral MaxillofacPathol*. 2014;18(Suppl 1):S117– S120. doi:10.4103/0973-029X.141321
64. Mimura H, Akita S, Fujino A, et al. Japanese clinical practice guide-lines for vascular anomalies 2017. *Jpn J Radiol*. 2020;38(4):287–342.
65. Goto K, Ozeki M, Yasue S, Endo S, Fukao T. A retrospective study of 2 or 3 mg/kg/day propranolol for infantile hemangioma. *Pediatr Int*. 2020;62(6):751–753. doi:10.1111/ped.14181
66. Baselga Torres E, BernabeuWittel J, van Esso Arbolave DL, et al. [Spanish consensus on infantile haemangioma]. *AnPediatr*. 2016;85 (5):256–265. Spanish. doi:10.1016/j.anpedi.2015.10.004
67. Itinteang T, Tan ST, Brasch HD, Vishvanath A, Day DJ. Primitive erythropoiesis in infantile haemangioma. *Br J Dermatol*. 2011;164 (5):1097–1100. doi:10.1111/j.1365-2133.2010.10187.x
68. Johansen ML, Mahendran G, Lawley LP. Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol. *PediatrDermatol*. 2021;38(4):800–805. doi:10.1111/pde.14651
69. Tan CE, Itinteang T, Leadbitter P, Marsh R, Tan ST. Low-dose propranolol regimen for infantile haemangioma. *J Paediatr Child Health*. 2015;51(4):419–424. doi:10.1111/jpc.12720
70. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. *Pediatrics*. 2013;131(1):128–140. doi:10.1542/peds.2012-1691

71. El Ezzi O, Hohlfeld J, de Buys Roessingh A. Propranolol in infantile haemangioma: simplifying pretreatment monitoring. *Swiss Med Wkly*. 2014;144:w13943.
72. Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas. *J Pediatr*. 2007;151 (6):684–689. doi:10.1016/j.jpeds.2007.04.055
73. Shin HT, Orlow SJ, Chang MW. Ulcerated haemangioma of infancy: a retrospective review of 47 patients. *Br J Dermatol*. 2007;156 (5):1050–1052. doi:10.1111/j.1365-2133.2007.07771.x
74. Ovidia SA, Landy DC, Cohen ER, Yang EY, Thaller SR. Local administration of beta-blockers for infantile hemangiomas: a systematic review and meta-analysis. *Ann Plast Surg*. 2015;74 (2):256–262. doi:10.1097/SAP.0000000000000390
75. Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: a systematic review. *Pediatr Dermatol*. 2013;30(2):182–191. doi:10.1111/pde.12089
76. Hermans DJ, Bauland CG, Zweegers J, van Beynum IM, van der Vleuten CJ. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. *Br J Dermatol*. 2013;168(4):837–843. doi:10.1111/bjd.12189
77. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. *Pediatrics*. 2011;128(2): e259–e266. doi:10.1542/peds.2010-0029
78. Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. *J Paediatr Child Health*. 2012;48(10):902–906. doi:10.1111/j.1440-1754.2012.02521.x
79. Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. *Pediatrics*. 2016;137(4): e20151754. doi:10.1542/peds.2015-1754
80. Pam N, Kridin K, Khamaysi Z. Propranolol for infantile hemangioma: evaluating efficacy and predictors of response and rebound growth. *Dermatol Ther*. 2021;34(3):e14936. doi:10.1111/dth.14936
81. Horbach SER, van der Horst C, Blei F, et al. Development of an international core outcome set for peripheral vascular malformations: the OVAMA project. *Br J Dermatol*. 2018;178(2):473–481. doi:10.1111/bjd.16029
82. Lee JC, Modiri O, England RW, Shawber CJ, Wu JK. Propranolol therapy in infantile hemangioma: it is not just about the beta. *Plast Reconstr Surg*. 2021;147(4):875–885. doi:10.1097/PRS.0000000000007699
83. Theiler M, Knopfel N, von der Heydt S, et al. Sleep behavior of infants with infantile hemangioma treated with propranolol—a cohort study. *Eur J Pediatr*. 2021;180(8):2655–2668. doi:10.1007/s00431-021-04147-3
84. Pandey V, Tiwari P, Imran M, Mishra A, Kumar D, Sharma SP. Adverse drug reactions following propranolol in infantile hemangioma. *Indian Pediatr*. 2021;58(8):753–755. doi:10.1007/s13312-021-2286-3
85. Xerfan EMS, Andersen ML, Facina AS, Tufik S, Tomimori J. Sleep disturbances as an adverse effect of propranolol use in children with infantile hemangioma. *World J Pediatr*. 2020;16(5):537–538. doi:10.1007/s12519-019-00335-2
86. Ji Y, Chen S, Yang K, et al. Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial. *JAMA Otolaryngol Head Neck Surg*. 2021;147(7):599–607. doi:10.1001/jamaoto.2021.0454
87. Ji Y, Chen S, Wang Q, et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. *Sci Rep*. 2018;8(1):4264. doi:10.1038/s41598-018-22787-8
88. Yang H, Hu DL, Shu Q, Guo XD. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. *World J Pediatr*. 2019;15(6):546–558. doi:10.1007/s12519-019-00285-9

89. Chang L, Ye X, Qiu Y, et al. Is propranolol safe and effective for outpatient use for infantile hemangioma? A prospective study of 679 cases from one center in China. *Ann Plast Surg.* 2016;76(5):559–563. doi:10.1097/SAP.0000000000000506
90. Thai T, Wang CY, Chang CY, Brown JD. Central nervous system effects of oral propranolol for infantile hemangioma: a systematic review and meta-analysis. *J Clin Med.* 2019;8(2):268. doi:10.3390/jcm8020268
91. Moyakine AV, Kerstjens JM, Spillekom-van Koulil S, van der Vleuten CJ. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years. *J Am Acad Dermatol.* 2016;75(1):59–63 e51. doi:10.1016/j.jaad.2016.02.1218
92. Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. *Br J Dermatol.* 2015;172(1):13–23. doi:10.1111/bjd.13379.
93. Ortaldo JR, Porter HR, Miller P, Stevenson HC, Ozols RF, Hamilton TC. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. *Cancer Res.* 1986;46:4414–4419.
94. Werner JA, Dunne AA, Folz BJ, et al. Current concepts in the classification, diagnosis and treatment of hemangiomas and vascular malformations of the head and neck. *Eur Arch Otorhinolaryngol.* 2001;258:141–149.
95. Kushner BJ. Hemangiomas. *Arch Ophthalmol.* 2000;118:835–836.
96. Léauté-Labrèze C, Voisard JJ, Moore N. Oral propranolol for infantile hemangioma. *N Engl J Med.* 2015;16:284–285.
97. Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. *Pediatrics.* 2013;131:99–108.
98. Zheng JW, Yang XJ, Wang YA, He Y, Ye WM, Zhang ZY. Intralesional injection of Pingyangmycin for vascular malformations in oral and maxillofacial regions: an evaluation of 297 consecutive patients. *Oral Oncol.* 2009;45:872–876.
99. Wang Z, Li K, Yao W, et al. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up. *Pediatr Blood Cancer.* 2015;62(4):577–580.
100. Moore A, Pinkerton R. Vincristine: can its therapeutic index be enhanced? *Pediatr Blood Cancer.* 2009;53:1180–1187.
101. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. *In Vitro Cell Dev Biol Anim.* 2002;38:298–304.
102. Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. *Arch Dermatol.* 2010;146:564–565.
103. Ge J, Zheng J, Zhang L, et al. Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. *Sci Rep.* 2016;6:19765.
104. Zhang L, Yuan W, Zheng J. Pharmacological therapies for infantile hemangiomas: A clinical study in 853 consecutive patients using a standard treatment algorithm. *Sci Rep.* 2016;6:21670.
105. Chen Z, Zheng J, Yuan M, et al. A novel topical nano-propranolol for treatment of infantile hemangiomas. *Nanomedicine: NBM.* 2015;11(5):1109–1115.
106. Munabi NC, England RW, Edwards AK, et al. Propranolol targets hemangioma stem cells via cAMP and mitogen-activated protein kinase regulation. *Stem Cells Transl Med.* 2016;5:45–55.